Joe Wolk

Pharma

J&J lifts 2025 sales guidance despite looming tariff threat

Even as tariffs start to impact its medtech business, Johnson & Johnson is lifting its sales guidance for 2025 thanks to a recent neuroscience buyout.

Fraiser Kansteiner Apr 15, 2025 11:55am

J&J's Kenvue spinoff provides $13.2B in potential M&A firepower

Aug 30, 2023 10:45am

J&J takes major hit from litigation cost in 2023's first quarter

Apr 18, 2023 11:15am

J&J is letting go of 64 staffers in Manhattan

Oct 20, 2022 10:59am

J&J reduces revenue forecast for 2022, dropping vaccine sales

Apr 19, 2022 11:08am

The 'new J&J' will be more aggressive about deals, CEO says

Jan 25, 2022 11:56am